Apimeds Pharmaceuticals US, Inc
Price Action
Technical Summary
WEAKENINGApimeds Pharmaceuticals US, Inc is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is moderate (RS Rating: 70), indicating performance broadly in line with the market. Earnings growth of 63% provides fundamental context to the price action. Investors should exercise caution due to high volatility (122% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.90 | -22.75% | BELOW |
| 50 SMA | $1.64 | -10.45% | BELOW |
| 100 SMA | $1.74 | -15.41% | BELOW |
| 150 SMA | $1.88 | -21.94% | BELOW |
| 200 SMA | $1.88 | -21.65% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is APUS in an uptrend right now?
APUS has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is APUS overbought or oversold?
APUS's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is APUS outperforming the market?
APUS has a Relative Strength (RS) Rating of 70 out of 99. APUS is performing about average compared to the market.
Where is APUS in its 52-week range?
APUS is trading at $1.47, which is 25% of its 52-week high ($5.97) and 10% above its 52-week low ($0.95).
How volatile is APUS?
APUS has a Beta of 0.82 and 52-week volatility of 122%. It's less volatile than the S&P 500 - generally more stable.